Psykey（CEOS）株式概要Psykey, Inc.は、エンテオジェニック、アダプトジェニック、ヌートロピックの成分および製剤の研究、開発、商品化に従事し、生活を改善し最適化するための機能性製品ラインを提供しています。 詳細CEOS ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析最新の財務報告は1年以上前のものである US市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( $2M )すべてのリスクチェックを見るCEOS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0075該当なし内在価値ディスカウントEst. Revenue$PastFuture-5m12016201920222025202620282031Revenue US$1.0Earnings US$0.1AdvancedSet Fair ValueView all narrativesPsykey, Inc. 競合他社Healthcare TriangleSymbol: NasdaqCM:HCTIMarket cap: US$4.9miTonic HoldingsSymbol: NasdaqCM:ITOCMarket cap: US$5.3miSpecimenSymbol: NasdaqCM:ISPCMarket cap: US$5.0mVSee HealthSymbol: NasdaqCM:VSEEMarket cap: US$7.6m価格と性能株価の高値、安値、推移の概要Psykey過去の株価現在の株価US$0.007552週高値US$0.01352週安値US$0.0006ベータ01ヶ月の変化4.04%3ヶ月変化227.96%1年変化-11.26%3年間の変化-70.42%5年間の変化-94.24%IPOからの変化-99.90%最新ニュースお知らせ • Jan 01CeCors, Inc. Appoints Michael Maher as Interim CEOCeCors, Inc. announced the appointment of Michael Maher as Interim Chief Executive Officer, effective immediately. Maher brings extensive leadership experience and a proven track record in driving operational efficiencies, compliance excellence and fiscal responsibility, positioning CeCors for sustainable growth. Maher has concurrently been appointed CEO and director of VETCOMM, CeCors' rapidly growing wholly-owned subsidiary focused on veteran claims benefits. His immediate priorities include streamlining operations, bolstering regulatory compliance, and implementing fiscal discipline to maximize value for the Company's client base and shareholders. Michael Maher is a former Navy Nuclear Submariner, U.S. Department of Justice Special Agent of the Federal Bureau of Investigation and has held numerous executive leadership roles globally. He is an alumnus of the FBI cademy, Navy Nuclear Power School, Oxford University, and a senior executive fellow with Harvard's John F. Kennedy School of Government. Under Maher's interim leadership, CeCors will continue to focus on its core mission while exploring new business opportunities and innovative solutions to meet the evolving needs of those they serve. Mr. Maher will oversee the implementation of VETCOMM's 2025 operating agenda, building on operational protocols as the company continues to grow, ensuring best practices across all operating segments.お知らせ • May 26CECORS, INC. Appoints Kate Monroe as Chief Executive OfficerCECORS, INC. announced the appointment of Marine Corps veteran Kate Monroe as its new Chief Executive Officer (CEO). With her extensive executive experience and strategic acumen, Monroe is poised to successfully lead CeCors in its strategic direction for greater market expansion and increased shareholder value. Kate Monroe is a highly accomplished professional with a distinguished journey. Born in Northern California, she embarked on a path of continuous growth and challenges from an early age. After attending Corban University, Kate recognized her need for a greater challenge, leading her to make the courageous decision to join the Marine Corps. She credits the Marine Corps for shaping her into the person she is, setting her on a trajectory for a successful life and career. Her military background serves as a catalyst, earning her respect and impacting the minds of those she interacts with. Kate's entrepreneurial spirit was instilled in her by her father, which propelled her to numerous successful ventures in various industries. Kate's most recent venture is the founding of VetComm, a veteran's education and benefits company focused on assisting United States veterans who qualify for underutilized annual benefits and owed compensation, resulting in billions of dollars of unclaimed benefits in the United States annually. Kate continues to shape the landscape of veteran support while also bringing her expertise and passion for driving the success of CeCors Inc. Kate Monroe is a tenacious and driven individual who thrives on empowering others to achieve success; her personal triumphs serve as a testament to her ability to inspire and lead. Monroe's appointment as CEO entails heightened responsibility in delivering value to shareholders while navigating the unique dynamics of the public markets. Her role encompasses key responsibilities, including strategic leadership, investor relations, and market expansion. As CEO, Monroe will provide strategic vision and leadership to CeCors, aligning the company's goals with the interests of its subsidiaries and shareholders. She will work closely with the board of directors and executive teams to define and execute the company's strategic direction. Recognizing the importance of maintaining strong relationships with shareholders and the investment community, Monroe will actively engage in investor relations activities. She will communicate the company's performance, growth strategies, and milestones to build trust and confidence among investors. Leading CeCors, Monroe will spearhead efforts to expand the company's market presence through its wholly-owned subsidiaries and continue to enhance shareholder value. She will explore opportunities for strategic partnerships, acquisitions, and organic growth to maximize market opportunities for the company.お知らせ • Dec 21Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp.Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp on December 19, 2022.お知らせ • Dec 07PsyKey Inc. Adds Dr. Shahiem Hartley to its Medical Advisory BoardPsyKey Inc. announced the addition of published medical and corporate wellness professional Dr. Shahiem Hartley to its Medical Advisory Board. Dr. Hartley completed a medical, masters, and pharmacy degree in South Africa before moving to Edmonton, Alberta, where he currently practices family medicine. During the pandemic, Dr. Hartley pivoted his business to assist patients with coping strategies, stress, and mental health management. Dr. Hartley then parlayed those strategies to develop a corporate mental wellness consulting company. Dr. Hartley offers individual and large-scale corporate enhancement and mental wellness seminars and training sessions.お知らせ • Nov 17Psykey, Inc. Appoints Michael J. Mccarthy as Member of Scientific & Medical Advisory BoardCECORS, INC. through its wholly owned subsidiary PsyKey Inc., announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board. Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties. Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement. With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.お知らせ • Nov 01CECORS, INC. Announces Appointment of John Gustin as Head of Global Business DevelopmentCECORS, INC. announced the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. As a consultant, Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news.最新情報をもっと見るRecent updatesお知らせ • Jan 01CeCors, Inc. Appoints Michael Maher as Interim CEOCeCors, Inc. announced the appointment of Michael Maher as Interim Chief Executive Officer, effective immediately. Maher brings extensive leadership experience and a proven track record in driving operational efficiencies, compliance excellence and fiscal responsibility, positioning CeCors for sustainable growth. Maher has concurrently been appointed CEO and director of VETCOMM, CeCors' rapidly growing wholly-owned subsidiary focused on veteran claims benefits. His immediate priorities include streamlining operations, bolstering regulatory compliance, and implementing fiscal discipline to maximize value for the Company's client base and shareholders. Michael Maher is a former Navy Nuclear Submariner, U.S. Department of Justice Special Agent of the Federal Bureau of Investigation and has held numerous executive leadership roles globally. He is an alumnus of the FBI cademy, Navy Nuclear Power School, Oxford University, and a senior executive fellow with Harvard's John F. Kennedy School of Government. Under Maher's interim leadership, CeCors will continue to focus on its core mission while exploring new business opportunities and innovative solutions to meet the evolving needs of those they serve. Mr. Maher will oversee the implementation of VETCOMM's 2025 operating agenda, building on operational protocols as the company continues to grow, ensuring best practices across all operating segments.お知らせ • May 26CECORS, INC. Appoints Kate Monroe as Chief Executive OfficerCECORS, INC. announced the appointment of Marine Corps veteran Kate Monroe as its new Chief Executive Officer (CEO). With her extensive executive experience and strategic acumen, Monroe is poised to successfully lead CeCors in its strategic direction for greater market expansion and increased shareholder value. Kate Monroe is a highly accomplished professional with a distinguished journey. Born in Northern California, she embarked on a path of continuous growth and challenges from an early age. After attending Corban University, Kate recognized her need for a greater challenge, leading her to make the courageous decision to join the Marine Corps. She credits the Marine Corps for shaping her into the person she is, setting her on a trajectory for a successful life and career. Her military background serves as a catalyst, earning her respect and impacting the minds of those she interacts with. Kate's entrepreneurial spirit was instilled in her by her father, which propelled her to numerous successful ventures in various industries. Kate's most recent venture is the founding of VetComm, a veteran's education and benefits company focused on assisting United States veterans who qualify for underutilized annual benefits and owed compensation, resulting in billions of dollars of unclaimed benefits in the United States annually. Kate continues to shape the landscape of veteran support while also bringing her expertise and passion for driving the success of CeCors Inc. Kate Monroe is a tenacious and driven individual who thrives on empowering others to achieve success; her personal triumphs serve as a testament to her ability to inspire and lead. Monroe's appointment as CEO entails heightened responsibility in delivering value to shareholders while navigating the unique dynamics of the public markets. Her role encompasses key responsibilities, including strategic leadership, investor relations, and market expansion. As CEO, Monroe will provide strategic vision and leadership to CeCors, aligning the company's goals with the interests of its subsidiaries and shareholders. She will work closely with the board of directors and executive teams to define and execute the company's strategic direction. Recognizing the importance of maintaining strong relationships with shareholders and the investment community, Monroe will actively engage in investor relations activities. She will communicate the company's performance, growth strategies, and milestones to build trust and confidence among investors. Leading CeCors, Monroe will spearhead efforts to expand the company's market presence through its wholly-owned subsidiaries and continue to enhance shareholder value. She will explore opportunities for strategic partnerships, acquisitions, and organic growth to maximize market opportunities for the company.お知らせ • Dec 21Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp.Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp on December 19, 2022.お知らせ • Dec 07PsyKey Inc. Adds Dr. Shahiem Hartley to its Medical Advisory BoardPsyKey Inc. announced the addition of published medical and corporate wellness professional Dr. Shahiem Hartley to its Medical Advisory Board. Dr. Hartley completed a medical, masters, and pharmacy degree in South Africa before moving to Edmonton, Alberta, where he currently practices family medicine. During the pandemic, Dr. Hartley pivoted his business to assist patients with coping strategies, stress, and mental health management. Dr. Hartley then parlayed those strategies to develop a corporate mental wellness consulting company. Dr. Hartley offers individual and large-scale corporate enhancement and mental wellness seminars and training sessions.お知らせ • Nov 17Psykey, Inc. Appoints Michael J. Mccarthy as Member of Scientific & Medical Advisory BoardCECORS, INC. through its wholly owned subsidiary PsyKey Inc., announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board. Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties. Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement. With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.お知らせ • Nov 01CECORS, INC. Announces Appointment of John Gustin as Head of Global Business DevelopmentCECORS, INC. announced the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. As a consultant, Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news.株主還元CEOSUS Healthcare ServicesUS 市場7D16.0%0.6%1.1%1Y-11.3%-38.3%28.7%株主還元を見る業界別リターン: CEOS過去 1 年間で-38.3 % の収益を上げたUS Healthcare Services業界を上回りました。リターン対市場: CEOSは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is CEOS's price volatile compared to industry and market?CEOS volatilityCEOS Average Weekly Movement58.3%Healthcare Services Industry Average Movement10.5%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: CEOSの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: CEOSの 週次ボラティリティ は、過去 1 年間で47%から58%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2002n/aMichael Maherwww.psykeyworld.comPsykey, Inc.は、エンテオジェニック、アダプトジェニック、ヌートロピックの成分および製剤の研究、開発、商品化に従事し、生活の改善と最適化を目的とした機能性製品ラインを提供しています。また、サイケデリック市場向けに、エンテオジェン系治療薬の組成、生物学的利用能、標的送達のための技術開発にも取り組んでいる。同社の小売製品には、機能性キノコのコーヒーや紅茶、経口サプリメント、シングルサーブドリンクミックスなどがある。同社は以前CeCors, Inc.として知られていたが、2021年8月に社名をPsykey, Inc.に変更した。サイキー社は2002年に設立され、カナダのトロントに本社を置いている。もっと見るPsykey, Inc. 基礎のまとめPsykey の収益と売上を時価総額と比較するとどうか。CEOS 基礎統計学時価総額US$2.36m収益（TTM）-US$5.01m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率CEOS は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CEOS 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$5.01m収益-US$5.01m直近の収益報告Sep 30, 2008次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%CEOS の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 21:35終値2026/05/22 00:00収益2008/09/30年間収益2007/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Psykey, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 01CeCors, Inc. Appoints Michael Maher as Interim CEOCeCors, Inc. announced the appointment of Michael Maher as Interim Chief Executive Officer, effective immediately. Maher brings extensive leadership experience and a proven track record in driving operational efficiencies, compliance excellence and fiscal responsibility, positioning CeCors for sustainable growth. Maher has concurrently been appointed CEO and director of VETCOMM, CeCors' rapidly growing wholly-owned subsidiary focused on veteran claims benefits. His immediate priorities include streamlining operations, bolstering regulatory compliance, and implementing fiscal discipline to maximize value for the Company's client base and shareholders. Michael Maher is a former Navy Nuclear Submariner, U.S. Department of Justice Special Agent of the Federal Bureau of Investigation and has held numerous executive leadership roles globally. He is an alumnus of the FBI cademy, Navy Nuclear Power School, Oxford University, and a senior executive fellow with Harvard's John F. Kennedy School of Government. Under Maher's interim leadership, CeCors will continue to focus on its core mission while exploring new business opportunities and innovative solutions to meet the evolving needs of those they serve. Mr. Maher will oversee the implementation of VETCOMM's 2025 operating agenda, building on operational protocols as the company continues to grow, ensuring best practices across all operating segments.
お知らせ • May 26CECORS, INC. Appoints Kate Monroe as Chief Executive OfficerCECORS, INC. announced the appointment of Marine Corps veteran Kate Monroe as its new Chief Executive Officer (CEO). With her extensive executive experience and strategic acumen, Monroe is poised to successfully lead CeCors in its strategic direction for greater market expansion and increased shareholder value. Kate Monroe is a highly accomplished professional with a distinguished journey. Born in Northern California, she embarked on a path of continuous growth and challenges from an early age. After attending Corban University, Kate recognized her need for a greater challenge, leading her to make the courageous decision to join the Marine Corps. She credits the Marine Corps for shaping her into the person she is, setting her on a trajectory for a successful life and career. Her military background serves as a catalyst, earning her respect and impacting the minds of those she interacts with. Kate's entrepreneurial spirit was instilled in her by her father, which propelled her to numerous successful ventures in various industries. Kate's most recent venture is the founding of VetComm, a veteran's education and benefits company focused on assisting United States veterans who qualify for underutilized annual benefits and owed compensation, resulting in billions of dollars of unclaimed benefits in the United States annually. Kate continues to shape the landscape of veteran support while also bringing her expertise and passion for driving the success of CeCors Inc. Kate Monroe is a tenacious and driven individual who thrives on empowering others to achieve success; her personal triumphs serve as a testament to her ability to inspire and lead. Monroe's appointment as CEO entails heightened responsibility in delivering value to shareholders while navigating the unique dynamics of the public markets. Her role encompasses key responsibilities, including strategic leadership, investor relations, and market expansion. As CEO, Monroe will provide strategic vision and leadership to CeCors, aligning the company's goals with the interests of its subsidiaries and shareholders. She will work closely with the board of directors and executive teams to define and execute the company's strategic direction. Recognizing the importance of maintaining strong relationships with shareholders and the investment community, Monroe will actively engage in investor relations activities. She will communicate the company's performance, growth strategies, and milestones to build trust and confidence among investors. Leading CeCors, Monroe will spearhead efforts to expand the company's market presence through its wholly-owned subsidiaries and continue to enhance shareholder value. She will explore opportunities for strategic partnerships, acquisitions, and organic growth to maximize market opportunities for the company.
お知らせ • Dec 21Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp.Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp on December 19, 2022.
お知らせ • Dec 07PsyKey Inc. Adds Dr. Shahiem Hartley to its Medical Advisory BoardPsyKey Inc. announced the addition of published medical and corporate wellness professional Dr. Shahiem Hartley to its Medical Advisory Board. Dr. Hartley completed a medical, masters, and pharmacy degree in South Africa before moving to Edmonton, Alberta, where he currently practices family medicine. During the pandemic, Dr. Hartley pivoted his business to assist patients with coping strategies, stress, and mental health management. Dr. Hartley then parlayed those strategies to develop a corporate mental wellness consulting company. Dr. Hartley offers individual and large-scale corporate enhancement and mental wellness seminars and training sessions.
お知らせ • Nov 17Psykey, Inc. Appoints Michael J. Mccarthy as Member of Scientific & Medical Advisory BoardCECORS, INC. through its wholly owned subsidiary PsyKey Inc., announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board. Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties. Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement. With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.
お知らせ • Nov 01CECORS, INC. Announces Appointment of John Gustin as Head of Global Business DevelopmentCECORS, INC. announced the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. As a consultant, Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news.
お知らせ • Jan 01CeCors, Inc. Appoints Michael Maher as Interim CEOCeCors, Inc. announced the appointment of Michael Maher as Interim Chief Executive Officer, effective immediately. Maher brings extensive leadership experience and a proven track record in driving operational efficiencies, compliance excellence and fiscal responsibility, positioning CeCors for sustainable growth. Maher has concurrently been appointed CEO and director of VETCOMM, CeCors' rapidly growing wholly-owned subsidiary focused on veteran claims benefits. His immediate priorities include streamlining operations, bolstering regulatory compliance, and implementing fiscal discipline to maximize value for the Company's client base and shareholders. Michael Maher is a former Navy Nuclear Submariner, U.S. Department of Justice Special Agent of the Federal Bureau of Investigation and has held numerous executive leadership roles globally. He is an alumnus of the FBI cademy, Navy Nuclear Power School, Oxford University, and a senior executive fellow with Harvard's John F. Kennedy School of Government. Under Maher's interim leadership, CeCors will continue to focus on its core mission while exploring new business opportunities and innovative solutions to meet the evolving needs of those they serve. Mr. Maher will oversee the implementation of VETCOMM's 2025 operating agenda, building on operational protocols as the company continues to grow, ensuring best practices across all operating segments.
お知らせ • May 26CECORS, INC. Appoints Kate Monroe as Chief Executive OfficerCECORS, INC. announced the appointment of Marine Corps veteran Kate Monroe as its new Chief Executive Officer (CEO). With her extensive executive experience and strategic acumen, Monroe is poised to successfully lead CeCors in its strategic direction for greater market expansion and increased shareholder value. Kate Monroe is a highly accomplished professional with a distinguished journey. Born in Northern California, she embarked on a path of continuous growth and challenges from an early age. After attending Corban University, Kate recognized her need for a greater challenge, leading her to make the courageous decision to join the Marine Corps. She credits the Marine Corps for shaping her into the person she is, setting her on a trajectory for a successful life and career. Her military background serves as a catalyst, earning her respect and impacting the minds of those she interacts with. Kate's entrepreneurial spirit was instilled in her by her father, which propelled her to numerous successful ventures in various industries. Kate's most recent venture is the founding of VetComm, a veteran's education and benefits company focused on assisting United States veterans who qualify for underutilized annual benefits and owed compensation, resulting in billions of dollars of unclaimed benefits in the United States annually. Kate continues to shape the landscape of veteran support while also bringing her expertise and passion for driving the success of CeCors Inc. Kate Monroe is a tenacious and driven individual who thrives on empowering others to achieve success; her personal triumphs serve as a testament to her ability to inspire and lead. Monroe's appointment as CEO entails heightened responsibility in delivering value to shareholders while navigating the unique dynamics of the public markets. Her role encompasses key responsibilities, including strategic leadership, investor relations, and market expansion. As CEO, Monroe will provide strategic vision and leadership to CeCors, aligning the company's goals with the interests of its subsidiaries and shareholders. She will work closely with the board of directors and executive teams to define and execute the company's strategic direction. Recognizing the importance of maintaining strong relationships with shareholders and the investment community, Monroe will actively engage in investor relations activities. She will communicate the company's performance, growth strategies, and milestones to build trust and confidence among investors. Leading CeCors, Monroe will spearhead efforts to expand the company's market presence through its wholly-owned subsidiaries and continue to enhance shareholder value. She will explore opportunities for strategic partnerships, acquisitions, and organic growth to maximize market opportunities for the company.
お知らせ • Dec 21Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp.Psykey, Inc. (OTCPK:CEOS) signed a binding letter of intent to acquire VetComm Corp on December 19, 2022.
お知らせ • Dec 07PsyKey Inc. Adds Dr. Shahiem Hartley to its Medical Advisory BoardPsyKey Inc. announced the addition of published medical and corporate wellness professional Dr. Shahiem Hartley to its Medical Advisory Board. Dr. Hartley completed a medical, masters, and pharmacy degree in South Africa before moving to Edmonton, Alberta, where he currently practices family medicine. During the pandemic, Dr. Hartley pivoted his business to assist patients with coping strategies, stress, and mental health management. Dr. Hartley then parlayed those strategies to develop a corporate mental wellness consulting company. Dr. Hartley offers individual and large-scale corporate enhancement and mental wellness seminars and training sessions.
お知らせ • Nov 17Psykey, Inc. Appoints Michael J. Mccarthy as Member of Scientific & Medical Advisory BoardCECORS, INC. through its wholly owned subsidiary PsyKey Inc., announce the appointment of Dr. Michael J. McCarthy, Ph.D. to its scientific and medical advisory board. Dr. McCarthy joins PsyKey with over 35 years of experience serving as a consultant to the biopharmaceutical industry and formulating high-impact pharmaceuticals and nutraceuticals. A biochemist and widely published author, Dr. McCarthy offers PsyKey his extensive expertise in securing biomedical patents and intellectual properties. Prior to joining PsyKey, Dr. McCarthy spent eight years at Scripps Research, ranked the most influential institution in the world for its impact on innovation as their biotechnology patent agent, while working on numerous ground-breaking technologies which have had major market influence. Among his many contributions to the biomedical field, Dr. McCarthy developed the "Agent/Enhancer" technology to increase the potency of biochemical factors used in therapeutics for anxiety, cancer, and sleep enhancement. With degrees in Biology and Physics from Benedictine College, Dr. McCarthy attended The Johns Hopkins University School of Medicine, where he participated in the Biochemistry, Cellular and Molecular Biology program. McCarthy went on to earn his Ph.D. from the Department of Biochemistry at Vanderbilt University. His Postdoctoral Studies in Endocrinology at Vanderbilt included developing viral and transgenic systems leading to the reversal of atherosclerosis in laboratory animals.
お知らせ • Nov 01CECORS, INC. Announces Appointment of John Gustin as Head of Global Business DevelopmentCECORS, INC. announced the appointment of John Gustin as head of global business development. John Gustin is a veteran corporate executive and scientific innovator with more than three decades of experience building some of the fastest-growing nutritional companies and brands in direct sales. Moreover, Gustin has led the effort to develop and patent numerous successful formulations for functional health and wellness products, and has authored numerous published articles related to immunology, diabetes, obesity and sports nutrition. One such patent, “# 5,914,326 Method for Promoting Weight and Fat Loss” was licensed to the former US Surgeon General Dr. C. Everett Koop. As a consultant, Gustin played a prominent role in the growth of numerous direct market giants, such as Nikken, Isotonix and NuSkin, providing guidance in product development and marketing strategies. He is generally credited with introducing the fat-burning, staple supplement Garcinia Cambogia to the U.S. market and helped to conduct the first human clinical studies. As a corporate member of United Sciences of America, Inc., Gustin helped the direct market company become the second fastest growing corporation in history with over $100 million in sales in its first nine months of operation. Gustin was also a founder and key executive of Evolv Health, LLC, makers of science-based functional beverages, which realized annual revenues exceeding $80 million. His discoveries and the brands he has helped develop have been viewed by millions on CNN, NBC, CBS, ABC and Fox news.
